CP 91149
- CAS No.
- 186392-40-5
- Chemical Name:
- CP 91149
- Synonyms
- CS-231;CP 91149;CP-91149 CP91149;CP 91149 USP/EP/BP;5-chloro-N-((2S,3R)-4-(dimethylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-1H-indole-2-carboxamide;5-Chloro-N-[(1S,2R)-3-(diMethylaMino)-2-hydroxy-3-oxo-1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide;[R-(R*,S*)]-5-Chloro-N-[3-(diMethylaMino)-2-hydroxy-3-oxo- 1-(phenylMethyl)propyl]-1H-indole-2-carboxaMide
- CBNumber:
- CB22543734
- Molecular Formula:
- C21H21ClN3O3
- Molecular Weight:
- 398.86274
- MDL Number:
- MFCD00954145
- MOL File:
- 186392-40-5.mol
- MSDS File:
- SDS
| Melting point | 190-192°C |
|---|---|
| storage temp. | 2-8°C |
| solubility | DMSO: >20mg/mL |
| form | powder |
| color | white to off-white |
| Stability | Hygroscopic |
| FDA UNII | O8EV00W45A |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P264-P270-P301+P312-P330-P501 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22 | |||||||||
| WGK Germany | 3 | |||||||||
| NFPA 704 |
|
CP 91149 price More Price(14)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | PZ0104 | CP-91149 ≥98% (HPLC) | 186392-40-5 | 5mg | $147 | 2024-03-01 | Buy |
| Sigma-Aldrich | PZ0104 | CP-91149 ≥98% (HPLC) | 186392-40-5 | 25mg | $576 | 2024-03-01 | Buy |
| Cayman Chemical | 17709 | CP 91,149 ≥98% | 186392-40-5 | 5mg | $62 | 2024-03-01 | Buy |
| Cayman Chemical | 17709 | CP 91,149 ≥98% | 186392-40-5 | 10mg | $109 | 2024-03-01 | Buy |
| Cayman Chemical | 17709 | CP 91,149 ≥98% | 186392-40-5 | 25mg | $211 | 2024-03-01 | Buy |
CP 91149 Chemical Properties,Uses,Production
Description
CP 91,149 is an inhibitor of human liver glycogen phosphorylase a (LGPa), muscle glycogen phosphorylase a (MGPa), and MGPb (IC50s = 0.13, 0.2, and 0.3 μM, respectively, in the presence of glucose). CP 91,149 is 5- to 10-fold less potent in the absence of glucose. In vitro, it inhibits glucagon-stimulated glycogenolysis in primary human hepatocytes (IC50 = 2.1 μM) and increases glycogen synthesis in rat hepatocytes at a concentration of 2.5 μM in the presence of 5 mM glucose. CP 91,149 inhibits brain GP (IC50 = 0.5 μM) and, at a concentration of 30 μM, inhibits glycogen accumulation and proliferation of A549 non-small cell lung carcinoma (NSCLC) cells that express endogenous brain GP. In vivo, CP 91,149 (25 mg/kg, p.o.) lowers the plasma glucose level in diabetic ob/ob mice within 3 hours of administration without producing hypoglycemia, but has no effect on normoglycemic, non-diabetic mice.
Chemical Properties
White Solid
Uses
Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression. Antitumor agent.
Biochem/physiol Actions
CP-91149 is a selective glycogen phosphorylase inhibitor.
in vitro
cp-91149 treatment suppressed glycogenolysis stimulated by glucagon in in primary human hepatocytes and isolated rat hepatocytes with ic50 value of 2.1 μm and 10–100 μm, respectively 1. inhibition of phosphorylase a by cp-91149 resulted in activation of glycogen synthase and translocation of the protein from a soluble to a particulate fraction, which mimicked the insulin- stimulated glycogen synthesis 2.
in vivo
treatment of cp-91149 on diabetic ob/ob mice at a dosage of 25–50 mg/kg was shown to lead to a rapid glucose lowering but did not change glucose levels in normoglycemic, nondiabetic mice 1.
target
GP
References
1. martin wh, hoover dj, armento sj, et al. discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. proceedings of the national academy of sciences of the united states of america. 1998;95(4):1776-1781.2. aiston s, coghlan mp, agius l. inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. european journal of biochemistry / febs. 2003;270(13):2773-2781.
CP 91149 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Alpha Biopharmaceuticals Co., Ltd | +86-411-39042497 +8613921981412 | sales@alphabiopharm.com | China | 886 | 58 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 | linda@hubeijusheng.com | CHINA | 28180 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-87569265 +86-18612256290 | 1056@dideu.com | China | 3734 | 58 |
| Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | sales@hbmojin.com | China | 12453 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6313 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 29321 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10523 | 58 |
| Nextpeptide Inc | +86-0571-81612335 +8613336028439 | sales@nextpeptide.com | China | 19915 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
